Cost of treatment drug for Tuberculosis slashed 70%

Tuberculosis treatment. (Photo: Jelle Krings/MSF)
Tuberculosis treatment. (Photo: Jelle Krings/MSF)

A French pharmaceutical giant has slashed the price of a critically important antibiotic used to prevent tuberculosis, giving new hope of beating the disease to millions of people – including hundreds of thousands living with HIV.

The cost of the drug, rifapentine, will be cut from U.S. $45 to $15 dollars for a recommended three-month course of treatment in 100 nations – including 48 in Africa – where TB is a big killer.

The discount deal was negotiated with the pharmaceutical company, Sanofi, by Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria, two initiatives which mobilise resources and finance to fight threats to public health.

Lelio Marmora, head of Unitaid, said the lifesaving drug has, until now, been completely unaffordable in developing countries. “This agreement will help transform political commitment to tangible action,” he added. Scientists quoted by AFP said the discount will be crucial to the United Nations aim of eradicating the disease by 2030.

The World Health Organisation says an estimated 1.7 billion people, a quarter of the world’s population, are infected by “latent” TB – they are infected but have no symptoms and are not contagious. Rifapentine, in combination with other medication, stops the infection from developing and being passed to others.

The announcement of the deal said that without treatment, five to 10% of those with latent TB would develop active TB. And those infected by HIV are up to 37 times more likely to do so.

Dr Tereza Kasaeva, director of WHO’s Global TB Programme, called the discount deal a “significant development”, adding that “efforts to make medicines more affordable and patient-friendly will facilitate national TB and HIV programmes quicken their pace to scale up preventive treatment services.”

The discount will have a significant impact on South Africa, which has high rates of TB infection and where many patients living with HIV/Aids die of TB.

Dr. Zweli Mkhize, the Minister of Health, said that “hundreds of thousands of vulnerable people can be initiated on this new treatment regimen starting next year, thanks to this price agreement.”

However, 12 civil society and community-based organizations across the world, while welcoming the development as a step forward, voiced reservations.

“We’re concerned that only 100 countries are eligible and that this is a discount rather than a true new lower ceiling price for all countries,” said Mike Frick of the Treatment Action Group, one of the 12 organisations.

The fact that rifapentine is unregistered in most high-TB-burden countries will be “a major impediment to access,” he added. “And we eagerly anticipate the entry of generic manufacturers of rifapentine and expect that they will enter the market at a price lower than the $15/patient-course discount granted by Sanofi.”


PT Mag Campaign AD

Support PREMIUM TIMES' journalism of integrity and credibility

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.


TEXT AD: To advertise here . Call Willie +2347088095401...

BE THE FIRST TO KNOW! Subscribe to our newsletter

* indicates required


Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application

All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.